GlaxoSmithKline chops up mature drugs portfolio for $3B sale

GlaxoSmithKline ($GSK) may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products: It's planning to sell off chunks of the portfolio in geographic areas, with Denmark's Lundbeck and India's Lupin are said to be in the running for regional pieces, likely in the U.S. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.